非小細胞肺癌市場規模、佔有率、成長分析、按類型、按治療方法、按最終用途行業、按地區 - 行業預測，2025-2032 年

2023年非小細胞肺癌市場規模為269.4億美元，從2024年的306.8億美元成長到2032年的869.4億美元，在預測期內（2025-2032年）預計將以複合年成長率成長。 。

將免疫查核點抑制劑（ICIs）引入一線治療顯著推動了非小細胞肺癌（NSCLC）領域的市場收益成長。非小細胞肺癌（NSCLC）佔全球肺癌患者的 80-85%，其盛行率促使主要企業專注於開發創新治療方法並提高現有選擇的有效性。這種成長也支持了肺癌作為全球癌症相關死亡主要原因的聲譽。非小細胞肺癌診斷數量的增加，加上已開發國家和新興國家社會意識的提高，進一步放大了市場活力。此外，主要市場參與者承諾將非小細胞肺癌治療納入其產品線以及研發投資的增加也是推動全球市場擴張的關鍵因素。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 監管環境
• 案例研究
• 技術進步

非小細胞肺癌市場規模：依類型

• 市場概況
• 腺癌
• 鱗狀細胞癌
• 大細胞癌
• 大細胞神經內分泌腫瘤

非小細胞肺癌市場規模：依治療方法

• 市場概況
• 化療
• 標靶治療
  • Bevacizumab
  • 奈西妥尤單抗
  • Ramucirumab
• 免疫療法
  • 納武單抗
  • Atezolizumab
• 其他

非小細胞肺癌市場規模：依最終用途產業

• 市場概況
• 醫院
• 居家護理
• 專科診所
• 其他

非小細胞肺癌市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• AstraZeneca（United Kingdom）
• Bristol-Myers Squibb Company（United States）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Bayer AG（Germany）
• Eli Lilly and Company（United States）
• GlaxoSmithKline plc（United Kingdom）
• Sanofi（France）
• AbbVie Inc.（United States）
• Johnson & Johnson（United States）
• Gilead Sciences, Inc.（United States）
• Amgen Inc.（United States）
• Boehringer Ingelheim GmbH（Germany）
• Daiichi Sankyo Company, Limited（Japan）
• Astellas Pharma Inc.（Japan）
• Biogen Inc.（United States）
• Regeneron Pharmaceuticals, Inc.（United States）

結論和建議

Non-Small Cell Lung Cancer Market size was valued at USD 26.94 Billion in 2023 and is poised to grow from USD 30.68 Billion in 2024 to USD 86.94 Billion by 2032, growing at a CAGR of 13.9% during the forecast period (2025-2032).

The introduction of immune checkpoint inhibitors (ICIs) for first-line treatment is significantly propelling market revenue growth in the non-small cell lung cancer (NSCLC) sector. Representing 80-85% of lung cancer cases globally, NSCLC's prevalence has prompted leading companies to focus on developing innovative therapies and enhancing the efficacy of existing options. This growth is also driven by lung cancer's reputation as a leading cause of cancer-related deaths worldwide. Rising diagnoses of NSCLC, coupled with increased public awareness in both developed and developing countries, are further amplifying market dynamics. Additionally, the commitment of major market players to incorporate NSCLC medications into their pipelines and their heightened investment in research and development are crucial factors driving the expansion of the global market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Non-Small Cell Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Non-Small Cell Lung Cancer Market Segmental Analysis

Global Non-Small Cell Lung Cancer Market is segmented by type, treatment, end-use industry and region. Based on type, the market is segmented into adenocarcinoma, squamous cell carcinoma, large cell carcinoma and large cell neuroendocrine tumors. Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy and others. Based on end-use industry, the market is segmented into hospitals, homecare, specialty clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Non-Small Cell Lung Cancer Market

The Non-Small Cell Lung Cancer (NSCLC) market is primarily driven by the escalating incidence of lung cancer attributed to factors such as smoking, air pollution, and increased vulnerability due to HIV infection, alongside a growing population. Additionally, the market is expected to expand with the rising number of regulatory approvals for innovative therapies tailored to NSCLC. Key industry players are prioritizing research and development investments to address the surging demand for effective treatment options. This combination of increasing disease prevalence and advancements in drug approvals is poised to significantly enhance the growth trajectory of the NSCLC market in the upcoming years.

Restraints in the Non-Small Cell Lung Cancer Market

A significant challenge facing the non-small cell lung cancer market is the high cost associated with its treatment options. While effective therapies such as chemotherapy, surgery, targeted therapies, radiation, and immunotherapy are available, they come with substantial financial burdens. This expensive nature of treatment poses a barrier to accessing care, limiting affordability for many patients and ultimately restricting market growth. Consequently, the financial implications of these therapies can hinder the overall advancement of the non-small cell lung cancer market, making it difficult for a broader population to benefit from available treatment options.

Market Trends of the Non-Small Cell Lung Cancer Market

The non-small cell lung cancer (NSCLC) market is witnessing significant growth, driven by a rise in diagnoses and heightened awareness across global regions, both developed and developing. Innovative treatment options, including targeted therapies and immunotherapies, are being actively developed by leading pharmaceutical companies, expanding their portfolios. Increased investment in research and development from major players is enhancing treatment availability and efficacy, further stimulating market momentum. Additionally, supportive regulatory frameworks and healthcare initiatives are improving patient access to advanced therapies, positioning the NSCLC market for sustained growth in the coming years as it aligns with evolving medical needs and technological advancements.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Non-Small Cell Lung Cancer Market Size by Type & CAGR (2025-2032)

• Market Overview
• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Large Cell Neuroendocrine Tumors

Global Non-Small Cell Lung Cancer Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted Therapy
  • Bevacizumab
  • Necitumumab
  • Ramucirumab
• Immunotherapy
  • Nivolumab
  • Atezolizumab
• Others

Global Non-Small Cell Lung Cancer Market Size by End-Use Industry & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Non-Small Cell Lung Cancer Market Size & CAGR (2025-2032)

• North America (Type, Treatment, End-Use Industry)
  • US
  • Canada
• Europe (Type, Treatment, End-Use Industry)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End-Use Industry)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End-Use Industry)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End-Use Industry)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations